186 related articles for article (PubMed ID: 34023105)
21. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
[TBL] [Abstract][Full Text] [Related]
22. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
[TBL] [Abstract][Full Text] [Related]
23. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.
Boennelycke M; Thomsen BM; Holck S
Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183
[TBL] [Abstract][Full Text] [Related]
24. The DNA mismatch repair system in sebaceous tumors: an update on the genetics and workup of Muir-Torre syndrome.
Dany M
Cutis; 2020 Mar; 105(3):E34-E37. PubMed ID: 32352449
[TBL] [Abstract][Full Text] [Related]
25. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
26. Immunosuppression and sebaceous tumors: a confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy.
Landis MN; Davis CL; Bellus GA; Wolverton SE
J Am Acad Dermatol; 2011 Nov; 65(5):1054-1058.e1. PubMed ID: 21550136
[TBL] [Abstract][Full Text] [Related]
27. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
[TBL] [Abstract][Full Text] [Related]
28. [Female patient with Muir-Torre syndrome].
Negraszus N; Jöhrens K; Bertelmann E
Ophthalmologe; 2010 Nov; 107(11):1059-62. PubMed ID: 20393721
[TBL] [Abstract][Full Text] [Related]
29. Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas.
Kwon MJ; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY
Pathol Res Pract; 2017 Jun; 213(6):654-658. PubMed ID: 28551389
[TBL] [Abstract][Full Text] [Related]
30. Site and tumor type predicts DNA mismatch repair status in cutaneous sebaceous neoplasia.
Singh RS; Grayson W; Redston M; Diwan AH; Warneke CL; McKee PH; Lev D; Lyle S; Calonje E; Lazar AJ
Am J Surg Pathol; 2008 Jun; 32(6):936-42. PubMed ID: 18551751
[TBL] [Abstract][Full Text] [Related]
31. The M2 macrophages infiltration of sebaceous tumors is linked to the aggressiveness of tumors but not to the mismatch repair pathway.
Frouin E; Alleyrat C; Godet J; Karayan-Tapon L; Sinson H; Morel F; Lecron JC; Favot L
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6445-6454. PubMed ID: 36763173
[TBL] [Abstract][Full Text] [Related]
32. MSH6 mutation in a family affected by Muir-Torre syndrome.
Kacerovska D; Cerna K; Martinek P; Grossmann P; Michal M; Ricar J; Kazakov DV
Am J Dermatopathol; 2012 Aug; 34(6):648-52. PubMed ID: 22814321
[TBL] [Abstract][Full Text] [Related]
33. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
Abbas O; Mahalingam M
J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
[TBL] [Abstract][Full Text] [Related]
35. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
[TBL] [Abstract][Full Text] [Related]
36. Sebaceous lesions of the skin.
Iacobelli J; Harvey NT; Wood BA
Pathology; 2017 Dec; 49(7):688-697. PubMed ID: 29078997
[TBL] [Abstract][Full Text] [Related]
37. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
38. Deceptively Innocent Façade of Sebaceous Carcinoma in Muir-Torre Syndrome.
Cox SV; Smith J
Dermatol Surg; 2021 Jun; 47(6):828-829. PubMed ID: 33038102
[No Abstract] [Full Text] [Related]
39. [Muir-Torre syndrome: rare association with duodenal carcinoma].
Bacha D; Deschamps L; Sauvanet A; Couvelard A
Ann Pathol; 2009 Dec; 29(6):495-8. PubMed ID: 20005439
[TBL] [Abstract][Full Text] [Related]
40. [Muir-Torre syndrome with previously undescribed frameshift mutation in the MSH2 gene].
Gilly B; Unholzer A; Strobl-Wildemann G; Haas C; Starz H; Welzel J
Hautarzt; 2013 Apr; 64(4):290-4. PubMed ID: 23229822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]